Clinical News
-
GLOBAL HEMATOLOGY | TIF Publishes EHA 2026 Key Takeaways
As a vital annual milestone, EHA2026 united thousands of hematologists, clinical researchers, and advocates from across the globe to address critical breakthroughs in the research, management, and cure of hematological…
Read More » -
RARE ANAEMIAS | RAIN Publishes EHA 2026 Research Highlights
Compiled by TIF’s Medical Advisor Dr. Michael Angastiniotis, and TIF’s Deputy Director, Ms. Lily Cannon, the publication offers a clear, patient-focused overview of recent developments across a broad spectrum of…
Read More » -
EU APPROVES MITAPIVAT | A New Treatment Milestone for Adults with α- or β-Thalassaemia
This decision is of particular importance because it covers a broad adult thalassaemia population, including both alpha- and beta-thalassaemia and both transfusion-dependent and non-transfusion-dependent disease. According to Agios Pharmaceuticals’ official…
Read More » -
APLASTIC ANAEMIA | ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Disease
Aplastic anaemia is a rare disorder characterized by bone marrow failure and reduced production of blood cells, resulting in pancytopenia and increased risks of infection, bleeding, and fatigue. Severe and…
Read More » -
wAIHA | Rilzabrutinib Receives FDA Breakthrough Therapy Designation
Warm autoimmune haemolytic anaemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells, leading to anemia and other serious complications, such as significant fatigue, dizziness,…
Read More » -
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden. The…
Read More » -
SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
The study explores the potential of memantine, a medication that has been safely used for many years in the treatment of Alzheimer’s disease. Researchers investigated whether this well-known, affordable drug…
Read More » -
FDA APPROVES AQVESME™ (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia
This regulatory decision marks a landmark milestone in the management of thalassaemia, as AQVESME is now the first and only therapy approved in the United States indicated for treating anaemia…
Read More » -
PUTTING PATIENTS FIRST IN CLINICAL RESEARCH | New EU Recommendations to Reduce Trials Bureaucracy
As Prof. Martin Dreyling, Chair of the Coalition for Reducing Bureaucracy, explains: “The current safety requirements for investigators are disproportionately burdensome, to the point that they may obscure relevant safety…
Read More » -
NEW STUDY | Pegcetacoplan Shows Potential in Managing CAD and wAIHA
This investigational therapy, which targets complement component C3, has demonstrated the ability to increase haemoglobin levels, reduce haemolysis, and improve fatigue scores, according to the study’s authors. Although not all…
Read More »